glp 1 approved for nash Resmetirom and GLP-1 agonists MASH: complementary rather than exclusive Nonalcoholic fatty liver disease: Current

Advancements in Combination Therapies: Presentations at the 2025 ADA meeting highlighted the potential of combining GLP-1 drugs with other metabolic agents to enhance treatment outcomes

Marks 2006

Fact Weight loss varies depending on metabolism, lifestyle, and individual health factors

High alcohol intake (350-420g/week in males, 280-350g/week in females) was identified as a particularly detrimental factor for cancer mortality in MetALD patients, significantly increasing the risk (HR 7.632, 95% CI 1.77232.869, p=0.006)

[DOI] [PMC free article] [PubMed] [Google Scholar] 1087.Zhou Z., Sheng X., Zhang Z., Zhao K., Zhu L., Guo G., Friedenberg S.G., Hunter L.S., Vandenberg-Foels W.S., Hornbuckle W.E., et al